EZH2 and central nervous system cancer: Patients with high 13-gene scores that concurrently harboured high TF expression had the poorest survival outcomes: glioma (EZH2: HR = 5.141, P < 0.0001; REST: HR = 3.646, P < 0.0001; SUZ12: HR = 3.596, P < 0.0001), clear cell renal cell (EZH2: HR = 2.854, P < 0.0001), papillary renal cell (EZH2: HR = 4.391, P = 0.0099) and liver (EZH2: HR = 2.685, P = 0.0005) cancers (Fig. 4c, f).